Study of Empagliflozin for Treating Adults with Pulmonary Arterial Hypertension to Assess Effectiveness and Safety

What this Trial Is About

Researchers are evaluating empagliflozin to see if it can help treat patients with pulmonary arterial hypertension PAH, a condition involving high blood pressure in the lungs arteries. The study aims to find out if empagliflozin, when added to standard treatments, can reduce pulmonary artery pressure and improve heart function. It will also assess the safety of empagliflozin compared to a placebo, focusing on any medical problems participants may experience while taking the drug. Participants will be randomly assigned to receive either 10 mg of empagliflozin or a placebo tablet once daily for 12 weeks, along with their usual PAH treatments. The study is double-blinded, meaning neither the participants nor the researchers know who receives which treatment during the trial. Participants will visit the clinic every 4 weeks for check-ups and tests during the treatment period. During the study, participants will keep a diary to record symptoms and medication intake. Researchers will evaluate outcomes such as the distance walked in 6 minutes, heart function tests, lung blood flow measurements, quality of life, and heart imaging results. These assessments will be done from enrollment through the 12-week treatment period to monitor the effects and safety of empagliflozin.

A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension